Roslin Cells Ltd., world leaders in the isolation of new clinical grade pluripotent stem cells, announced today that it has now moved to the new Scottish Centre for Regenerative Medicine at Edinburgh BioQuarter.
Roslin Cells and Pfizer Limited have signed an agreement for Pfizer to evaluate Roslin’s GMP quality Pluripotent Stem Cells (PSC).
Roslin Cells Ltd., world leaders in the isolation of new clinical grade undifferentiated stem cells, and Advanced Cell Technology, Inc. (ACT), one of the leading US companies in regenerative medicine, announced that they have entered into a collaboration agreement to establish new clinical grade human embryonic stem cell (hESC) lines using ACTs patented, proprietary “single-cell blastomere” technique.
Roslin Cells Ltd., world leaders in the isolation of new clinical grade undifferentiated stem cells, announced today that is has successfully retained certification to ISO 9001, the internationally recognised management system standard which serves as a benchmark for quality management systems.
Sistemic Ltd and Roslin Cells Ltd today signed a Memorandum of Understanding to promote the development of new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening.
On November 18 Roslin Cells Ltd. won the Midlothian and East Lothian Chamber of Commerce High Growth Award for 2010.
Edinburgh, UK, 04 October 2010 – Roslin Cells Ltd., a leading provider of clinical grade pluripotent stem cells, announced today the Roslin Cell Therapy Partner Program.
Roslin Cells Ltd. has entered a worldwide, in kind research collaboration agreement with Lonza, Walkersville, Inc. (US) for the development of customized cell culture media and processes for the production of pluripotent stem cells (PSCs) to advance the field of cell therapy.